Results 191 to 200 of about 2,472,934 (283)

Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. [PDF]

Drug Saf, 2020
Davies M, Osborne V, Lane S, Roy D, Dhanda S, Evans A, Shakir S.   +6 more
europepmc   +2 more sources

A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review. [PDF]

J Clin Med
Rubiu E, Restelli F, Nazzi V, Mazzapicchi E, Bonomo G, Veiceschi P, Alfiero T, Agresta G, Locatelli D, Dario A.   +9 more
europepmc   +1 more source

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). [PDF]

Vaccine, 2022
Leav B, Straus W, White P, Leav A, Gaines T, Maggiacomo G, Kim D, Smith ER, Gurwith M, Chen RT, Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO ex-V3SWG.   +10 more
europepmc   +1 more source

Changes in Immune‐Inflammation Status and Acute Ischemic Stroke Prognosis in Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Inflammation is a critical risk factor for poor outcomes in cerebral infarction. Prior studies focused primarily on baseline inflammation status, neglecting dynamic longitudinal changes. We try to investigate the association between immune‐inflammation status alterations and stroke prognosis, and evaluated three systemic biomarkers'
Songfang Chen, Wenting Huang, Yitian Liu, Xuan Chen, Buyu Ke, Qian Shen, Hanyu Cai, Jing Sun, Yan Li, Yungang Cao, Beilei Hu, Keyang Chen   +11 more
wiley   +1 more source

Benefit-Risk Assessment of ChatGPT Applications in the Field of Diabetes and Metabolic Illnesses: A Qualitative Study. [PDF]

Clin Med Insights Endocrinol Diabetes
Jairoun AA, Al-Hemyari SS, Shahwan M, Al-Qirim T, Shahwan M.   +4 more
europepmc   +1 more source

Benefit-risk methodology project:work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment [PDF]

, 2011

core  

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

Author Response to Comment on: "Benefit-Risk Assessment of ChatGPT Applications in the Field of Diabetes and Metabolic Illnesses: A Qualitative Study". [PDF]

Clin Med Insights Endocrinol Diabetes
Jairoun AA, Al-Hemyari SS, Shahwan M, Al-Qirim T, Shahwan M.   +4 more
europepmc   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan. [PDF]

Clin Pharmacol Ther, 2022
Nishioka K, Makimura T, Ishiguro A, Nonaka T, Yamaguchi M, Uyama Y.   +5 more
europepmc   +1 more source